Ardelyx Inc
Company Profile
Business description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Contact
400 Fifth Avenue
Suite 210
WalthamMA02451
USAT: +1 510 745-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
395
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,063.40 | 33.90 | 0.38% |
CAC 40 | 7,827.45 | 44.57 | -0.57% |
DAX 40 | 23,666.81 | 55.48 | 0.23% |
Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
FTSE 100 | 9,250.43 | 27.11 | 0.29% |
HKSE | 26,553.58 | 34.93 | 0.13% |
NASDAQ | 22,497.86 | 75.62 | -0.33% |
Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
S&P 500 | 6,637.97 | 18.95 | -0.28% |
S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
SSE Composite Index | 3,861.75 | 8.11 | 0.21% |